Ramorelix

Ramorelix is a luteinizing-hormone-releasing hormone (LHRH) antagonist. Ramorelix can inhibit tumor progression in vivo. Ramorelix can be studied in anti-cancer research[1].

Product Specifications

CAS Number

127932-90-5

UNSPSC

12352209

Target

GnRH Receptor

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(NNC(N)=O)[C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H](CO[C@H]2[C@@H]([C@@H]([C@H]([C@H](C)O2)O)O)O)NC([C@H](CC3=CC=C(O)C=C3)NC([C@H](CO)NC([C@@H](CC4=CNC5=C4C=CC=C5)NC([C@@H](CC6=CC=C(Cl)C=C6)NC([C@@H](CC7=CC=C8C=CC=CC8=C7)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1

Molecular Formula

C74H95ClN16O18

Molecular Weight

1532.10

References & Citations

[1]Stoeckemann, K., & Sandow, J. (1993) . Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. Journal of cancer research and clinical oncology, 119 (8), 457-462.